Antihypertensive therapy in diabetes: The legacy effect and RAAS blockade

Current Hypertension Reports

Volumn 13, Issue 4, 2011, Pages 318-324

  Volpe, Massimo ^a,b   Cosentino, Francesco ^a   Tocci, Giuliano ^a   Palano, Francesca ^a   Paneni, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

High blood pressure; Keywords Diabetes; Legacy effect; Oxidative stress; Renin angiotensin aldosterone system; Vascular remodeling

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LOSARTAN; NISOLDIPINE; OLMESARTAN; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART INJURY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; TREATMENT RESPONSE; VASCULAR DISEASE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS;

EID: 80052562488     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-011-0205-z     Document Type: Article

References (50)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
2. mit dot;Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89. This is a post-trial monitoring follow-up of the UKPDS study, showing for the first time that early and intensive treatment of hyperglycemia provides sustained benefits in patients with type 2 diabetes.
3. mit dot; Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565-76. This substudy of the UKPDS trial is a post-monitoring follow-up aimed at assessing whether benefits of an intensive blood pressure lowering strategy were maintained during the following years in hypertensive patients with type 2 diabetes. The authors found that intensive blood pressure lowering does not confer cardiovascular protection after switching to a conventional antihypertensive regimen.
4. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53.
5. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006 Diabetes Care. 2009;32:287-94.
6. Hypertension in Diabetes Study (HDS). II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens. 1993;11:319-25.
7. Ball SG. Benefits of blood pressure reduction in diabetic patients. J Hypertens Suppl. 2003;21:S31-6. (Pubitemid 37082787)
8. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003;138:593-602.
9. Sciarretta S, Paneni F, Palano F, et al. Role of the reninangiotensin- aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci. 2009;116:467-77.
10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
11. Sleight P, Redon J, Verdecchia P, et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27:1360-9.
12. Patel A. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40. (Pubitemid 47362321)
13. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603. (Pubitemid 28172941)
14. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-6. (Pubitemid 29087980)
15. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-52. (Pubitemid 28108434)
16. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with Type 2 diabetes and microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-8.
17. Viberti G, Wheeldon NM. Micro Albuminuria reduction with VAL sartan (MARVAL) study investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672-8. (Pubitemid 34851925)
18. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. RENAAL Study Investigators. N Engl J Med. 2001;345:861-9.
19. Heinig RE. What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. Diab Obes Metab. 2002;4 Suppl 1:S19-25. (Pubitemid 34285276)
20. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. Bergamo nephrologic diabetes complications trial (BENEDICT) investigators. N Engl J Med. 2004;351:1941-51.
21. Haller H, Ito S, Izzo JL, et al. Prevention of microalbuminuria in type 2 diabetes (Roadmap Trial): 6A.02. Oral presentation at the annual meeting of the European Society of Hypertension (Oslo, Norway, June 18-21, 2010). J Hypertens 2010;28:e233. The ROADMAP trial is a very recent study designed to ascertain whether treatment with olmesartan can prevent or delay the occurrence of microalbuminuria in patients with type 2 diabetes. The authors found that olmesartan was able to reduce microalbuminuria by 23% in 5,000 patients with hypertension and type 2 diabetes.
22. Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens. 2007;25:1751-62. (Pubitemid 47356612)
23. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136.
24. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res. 2000;87:1123-32.
25. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci. 2007;112:375-84. (Pubitemid 46587452)
26. Singh VP, Baker KM, Kumar R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol. 2008;294:H1675-84. (Pubitemid 351490598)
27. McMurray JJ, Holman RR, Haffner SM, et al. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477-90. This trial clearly shows that RAAS antagonism prevents the development of diabetes in patients with impaired glucose tolerance and cardiovascular risk factors. These findings are in line with experimental evidence showing that RAAS hyperactivation impairs glucose metabolism and insulin sensitivity.
28. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of anti hypertensive drugs: a network meta-analysis. Lancet. 2007;369:201-7. (Pubitemid 46111014)
29. Tocci G, Paneni F, Palano F, et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a metaanalysis of placebo-controlled clinical trials. Am J Hypertens. 2011 Feb 17 (Epub ahead of print).
30. Hsieh TJ, Fustier P, Zhang SL, et al. High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology. 2003;144:4338-49. (Pubitemid 37204833)
31. Choi KC, Kim NH, An MR, Kang DG, Kim SW, Lee J. Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int Suppl. 1997;60:S23-7.
32. · Toma I, Kang JJ, Sipos A, et al. Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest. 2008;118:2526-34. This study provide an additional mechanism by which hyperglycemia upregulates RAAS activity. In this investigation, the authors found that accumulation of succinate, a citric cycle intermediate, binds and activates the G-protein-coupled receptor GPR91, directly triggering the release of renin. (Pubitemid 351949780)
33. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57:3297-306.
34. Parving HH, Persson F, Lewis JB, Lewis EJ. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-46. (Pubitemid 351793017)
35. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24:1663-71.
36. Ichihara A, Sakoda M, Kurauchi-Mito A, et al. Possible roles of human (pro)renin receptor suggested by recent clinical and experimental findings. Hypertens Res. 2010;33:177-80.
37. Lavrentyev EN, Malik KU. High glucose-induced Nox1-derived superoxides downregulate PKC-betaII, which subsequently decreases ACE2 expression and ANG(1-7) formation in rat VSMCs. Am J Physiol Heart Circ Physiol. 2009;296:H106-18.
38. Reinemund J, Seidel K, Steckelings UM, et al. Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes. Biochem Pharmacol. 2009;77:1795-805.
39. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57:3297-306.
40. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527-32. (Pubitemid 37176462)
41. Rizzoni D, Porteri E, Boari GE, et al. Prognostic significance of smallartery structure in hypertension. Circulation. 2003;108:2230-5. (Pubitemid 37363040)
42. Izzard AS, Rizzoni D, Agabiti-Rosei E, Heagerty AM. Small artery structure and hypertension: adaptive changes and target organ damage. J Hypertens. 2005;23:247-50. (Pubitemid 40279623)
43. Rizzoni D, Porteri E, De Ciuceis C, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension. 2005;45:659-65. (Pubitemid 40418362)
44. Savoia C, Touyz RM, Endemann DH, et al. Angiotensin receptor blocker added to previous anti hypertensive agents on arteries of diabetic hypertensive patients. Hypertension. 2006;48:271-7. (Pubitemid 44309823)
45. Kim SM, Chen L, Faulhaber-Walter R, et al. Regulation of renin secretion and expression in mice deficient in beta1- and beta2- adrenergic receptors. Hypertension. 2007;50:103-9. (Pubitemid 46986017)
46. · Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91. This trial demonstrates that in patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification has sustained beneficial effects on vascular complications and rates of death from any cause and from cardiovascular causes. These results highlight the importance of lifestyle changes and global cardiovascular risk reduction in the diabetic population. (Pubitemid 351214285)
47. · Lind M, Odén A, Fahlén M, Eliasson B. The shape of the metabolic memory of HbA1c: re-analysing the DCCT with respect to time-dependent effects. Diabetologia. 2010;53:1093-8. In this report, Lind et al. analyzed the impact of glycosylated hemoglobin and found that HbA1c still had an important impact on the development of microvascular complications for up to 8 years. In other words, this study demonstrates that initially high levels of HbA1c are a strong predictor of events even if normalization of such values is achieved in ensuing years.
48. · ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. In the ACCORD trial, diabetic patients achieving a BP target less than 120 mm Hg had an increased rate of myocardial infarction. These findings suggest that an intensive BP-lowering strategy may prove detrimental in diabetic patients.
49. Sleight P, Redon J, Verdecchia P, et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27:1360-9.
50. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-28.